SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2132Safe to assume REGN will get breakthrough status as well? Is it possible to seeFelix B-6/15/2017
2131Seams that Abs-manufacturing will be kay point in next few years. Too bad, SanofMiljenko Zuanic-6/14/2017
2130Probably, .. seekingalpha.comMiljenko Zuanic-6/14/2017
2129Does anyone has pass for Goldman Sachs investor conference , @ Rancho Palos VerdMiljenko Zuanic-6/9/2017
2128Was just going to post this and ya beat me to it...Felix B-6/8/2017
2127Is this sarilumab PROBLEM too???? (ACTEMRA): statnews.com rxlist.com Label for Miljenko Zuanic-6/7/2017
2126Means that as of cut-off date more than 1/2 subjects still receive treatment andMiljenko Zuanic-6/7/2017
2125Question on the recent REGN2810 release: "Median progression-free survivalFelix B-6/6/2017
2124<But is the court so foresightful?> IF they are not, Pandora box is open!Miljenko Zuanic-6/6/2017
2123I think the important point is that "not all me too drugs are created equalBiotech Jim-6/6/2017
2122Today oral argument (Amgen v Sanofi, Repatha v Praluent), cafc.uscourts.gov , iMiljenko Zuanic-6/6/2017
2121So looks like both REGN and PFE read out 2018Q1Felix B-6/2/2017
2120They are trying titration regimen: clinicaltrials.gov clinicaltrials.govMiljenko Zuanic-6/2/2017
2119Any updates on Pfizers program?Felix B-6/2/2017
2118Fasinumab moving forward! Is Teva stupid or Sanofi smart (like with Eylea!)? clMiljenko Zuanic-6/1/2017
2117Nice launch of our second blockbuster in the making... From a Leerink report, hBiotech Jim-5/24/2017
2116Amendments of the Fasinumab LTS P3 protocol are positive for this program: clinMiljenko Zuanic-5/18/2017
2115Amendments of the Fasinumab LTS P3 protocol are positive for this program: clinMiljenko Zuanic-5/18/2017
2114Not bad for P1: abstracts.asco.org 50% ORR with some CR is very good to start pMiljenko Zuanic-5/17/2017
2113Dupi cost effective by ICER: icer-review.orgMiljenko Zuanic-5/12/2017
2112I am bit surprise that there is no single comment on this news (also on tweeter)Miljenko Zuanic25/11/2017
2111There is something specific in Dupi, relative to other Abs toward IL-13 or IL-4:Miljenko Zuanic-5/10/2017
2110CC transcript: seekingalpha.com <I'd like to spend a few moments focusingMiljenko Zuanic-5/4/2017
2109Did you catch the journal source/citation for the long term Eylea data that GY wBiotech Jim-5/4/2017
2108From the 1Q CC: <Based on a qualitative market research survey we conducted iMiljenko Zuanic-5/4/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News